Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | CD38 | P28907 | 2/20 | 0.37 |
| ▸ | LCK | P06239 | 3/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | TEK | Q02763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781265 | 0.86 | EPHX2 (0.41) | ULK1KMT2ALMNATP53MAPK1 | |
| SCHEMBL3428599 | 0.66 | LMNA (0.30) | LMNATP53 | |
| SCHEMBL31645683 | 0.65 | P2RX7 (0.47) | CD38EPHX2P2RX7PTGS2 | |
| SCHEMBL27806964 | 0.64 | ULK1 (0.39) | ULK1KMT2ALMNATP53MAPK1 | |
| SCHEMBL1506212 | 0.61 | RIPK1 (0.43) | MAPK1P2RX7 | |
| SCHEMBL11476667 | 0.60 | PDK2 (0.46) | KMT2ALMNATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL1847415 | 0.60 | EPHX2 (0.58) | KMT2ASMN1; SMN2ALDH1A1TSHRMEN1 | |
| SCHEMBL8914214 | 0.60 | SMN1; SMN2 (0.51) | KMT2ALMNASMN1; SMN2TSHRCD38 | |
| SCHEMBL15606532 | 0.60 | ULK1 (0.44) | ULK1KMT2ALMNAALDH1A1P2RX3 | |
| SCHEMBL3410830 | 0.59 | ALDH1A1 (0.56) | LMNASMN1; SMN2NPSR1ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778974-B2 | Trisubstituted 1,2,4 triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-8778974-B2 | Trisubstituted 1,2,4 triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| EP-2257535-B1 | TRISUBSTITUTED 1,2,4-TRIAZOLES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-06 | — | — | EP | disclosed |
| EP-2257535-B1 | TRISUBSTITUTED 1,2,4-TRIAZOLES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-06 | — | — | EP | disclosed |
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| WO-2009115547-A1 | TRISUBSTITUTED 1, 2, 4 -TRIAZOIIES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | CHRNA1, CHRNA5, CHRNE | ULK1 2017/4885KMT2A 1438/4885LMNA 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.